[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 681,274
  • Shares Outstanding, K 98,450
  • Annual Sales, $ 0 K
  • Annual Income, $ -174,330 K
  • EBIT $ -179 M
  • EBITDA $ -179 M
  • 60-Month Beta 2.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.01

Options Overview Details

View History
  • Implied Volatility 224.39% (+31.94%)
  • Historical Volatility 56.86%
  • IV Percentile 44%
  • IV Rank 12.93%
  • IV High 1,154.33% on 11/07/25
  • IV Low 86.30% on 06/16/25
  • Expected Move (DTE 32) 1.92 (27.76%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 154
  • Volume Avg (30-Day) 240
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 5,539
  • Open Int (30-Day) 4,762
  • Expected Range 5.00 to 8.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 6
  • High Estimate $-0.35
  • Low Estimate $-0.51
  • Prior Year $-0.42
  • Growth Rate Est. (year over year) +2.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.74 +2.67%
on 05/15/26
8.81 -21.41%
on 04/20/26
-1.40 (-16.83%)
since 04/15/26
3-Month
5.23 +32.31%
on 02/17/26
8.87 -21.95%
on 04/14/26
+0.73 (+11.79%)
since 02/13/26
52-Week
2.61 +165.13%
on 05/19/25
8.87 -21.95%
on 04/14/26
+4.33 (+167.18%)
since 05/15/25

Most Recent Stories

More News
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines...

SLDB : 6.92 (-9.31%)
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory...

SLDB : 6.92 (-9.31%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...

SLDB : 6.92 (-9.31%)
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters -  CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid...

SLDB : 6.92 (-9.31%)
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

- Orphan drug designation from the European Commission underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - ...

SLDB : 6.92 (-9.31%)
Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

SLDB : 6.92 (-9.31%)
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-  Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003...

SLDB : 6.92 (-9.31%)
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex...

SLDB : 6.92 (-9.31%)
Solid Biosciences Announces Oversubscribed $240 Million Private Placement

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today...

SLDB : 6.92 (-9.31%)
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today...

SLDB : 6.92 (-9.31%)

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 8.11
2nd Resistance Point 7.80
1st Resistance Point 7.36
Last Price 6.92
1st Support Level 6.61
2nd Support Level 6.30
3rd Support Level 5.86

See More

52-Week High 8.87
Last Price 6.92
Fibonacci 61.8% 6.48
Fibonacci 50% 5.74
Fibonacci 38.2% 5.00
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.